BAYRY vs CTVA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAYRY and CTVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAYRY and CTVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bayer AG is a Leverkusen-based life sciences company with three divisions. Crop Science (seeds, traits and crop protection, much of it inherited from the ~$63 billion Monsanto acquisition in 2018) is the largest by sales. Pharmaceuticals sells prescription drugs such as the anticoagulant Xarelto, the prostate cancer drug Nubeqa, the kidney and heart drug Kerendia, the eye drug Eylea outside the US, and the menopause treatment Lynkuet (elinzanetant). Consumer Health sells over-the-counter brands including Aspirin, Aleve, Claritin, Bepanthen and One A Day. Group sales were ~EUR 45.6 billion (~$51 billion) in 2025, and the primary listing is on Xetra in Frankfurt under BAYN, where it is a DAX member. BAYRY is a sponsored ADR that trades over the counter in the US, with four ADRs representing one ordinary share.

Full BAYRY guide

Corteva was formed in 2019 when DowDuPont spun off its agriculture business, and for most of its life it ran two segments: Seed (genetically improved corn, soybean, canola, and other crop seeds) and Crop Protection (herbicides, insecticides, fungicides, and biological products). That structure ended in October 2026, when Corteva completed the separation of its seed operations into a new independent company, Vylor Inc., which trades under the ticker VYLR. Corteva keeps the NYSE listing and the CTVA ticker as a crop protection and digital agriculture business, with a standalone revenue base reported at about $7.5 billion and projected 2025 EBITDA of about $1.4 billion. Headquartered in Indianapolis, Indiana. Chuck Magro has been CEO since 2021.

Full CTVA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAYRY drivers: Closing out the Roundup litigation; Crop Science margin recovery.
• CTVA drivers: A pure crop protection company after the Vylor spin-off; Biological products growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. For CTVA, commodity crop price cycles affect farmer purchasing power and Corteva revenue, and the company no longer has the seed business to cushion a weak chemistry year.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAYRY if you believe its drivers more; CTVA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAYRY and CTVA guides.

BAYRY. At ~EUR 44 a share, Bayer trades at roughly 9 to 11 times its 2026 core EPS guidance and around 7 to 8 times enterprise value to EBITDA before special items, a discount to large European pharma and agrochemical peers that reflects leverage and residual litigation risk. Reported net income has been negative (a net loss of ~EUR 3.6 billion in 2025, driven by litigation provisions), so trailing P/E figures on data sites can look meaningless or distorted. The dividend has been EUR 0.11 per share, a yield well under 1%, while cash goes to settlements and debt reduction.

CTVA. Post-spin Corteva is valued as a mid-cap crop chemicals company: about 11 times forward earnings and roughly $8.6 billion of market value, a long way from the premium the combined seed-and-chemistry company carried. Trailing figures on data sites (a P/E near 8, a dividend yield above 5%, TTM net income of ~$126 million) mix pre- and post-separation periods and per-share bases, so they are not a clean guide yet. UBS cut its price target to $15 from $90 with a Neutral rating; the cut tracks the smaller standalone company rather than a change in view, and the November 11, 2026 report will give the first clean standalone baseline.

Headline figures (approximate, October 2026): BAYRY shows revenue (fy2025) ~EUR 45.6 billion (~$51 billion), ebitda before special items (fy2025) ~EUR 9.7 billion; 2026 guide ~EUR 9.6 to 10.1 billion, core eps guidance (2026) ~EUR 4.10 to 4.80 per share (new methodology), share price ~EUR 44 on Xetra; BAYRY ~$12.2 (4 ADRs = 1 share); CTVA shows standalone revenue base (crop protection and digital) ~$7.5 billion, per post-spin reports, standalone ebitda (2025, projected) ~$1.4 billion, operating margin (ttm, yahoo basis) ~13%, market cap ~$8.6 billion at $12.94 (Oct 16, 2026).

BAYRY and CTVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAYRY and CTVA exposure against your real portfolio. It is not an investment adviser.